SOMERVILLE, Mass. (PRWEB) October 12, 2020
Glint Pharmaceuticals announces the release of a video interview by the INTERPHEX 2020 conference. The interview includes a discussion with the Glint senior management team to highlight the company’s drug delivery contact lens technology and related market opportunities in glaucoma and infectious diseases.
The INTERPHEX conference is the premier pharmaceutical, biotechnology and device development and manufacturing event. INTERPHEX brings together over 10,000 global industry professionals and companies to exhibit, network and demonstrate leading edge products. The ability to transition to a virtual format this year has allowed the conference to reach a global audience.
Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance.